- Home
- TLN vs UTHR Comparison
TLN vs UTHR Comparison
Compare TLN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLN | UTHR |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 20.3B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | TLN | UTHR |
|---|---|---|
| Price | $354.06 | $488.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $415.38 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 900.2K | 424.3K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.08 |
| EPS | 4.55 | ★ 26.38 |
| Revenue | $2,343,000,000.00 | ★ $3,128,400,000.00 |
| Revenue This Year | $13.07 | $13.64 |
| Revenue Next Year | $73.72 | $5.78 |
| P/E Ratio | $77.79 | ★ $18.55 |
| Revenue Growth | ★ 16.22 | 13.50 |
| 52 Week Low | $158.08 | $266.98 |
| 52 Week High | $451.28 | $492.62 |
Technical Indicators
Market Signals| Indicator | TLN | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 38.89 | 68.10 |
| Support Level | $359.52 | $470.13 |
| Resistance Level | $377.08 | $492.62 |
| Average True Range (ATR) | 18.51 | 10.72 |
| MACD | -1.00 | -0.53 |
| Stochastic Oscillator | 11.31 | 89.55 |
Price Performance
Historical ComparisonAbout TLN Talen Energy Corporation Common Stock
Talen Energy Corp is an independent power producer and energy infrastructure company. The company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States. The group produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, including PJM and WECC, with its generation fleet located in the Mid-Atlantic and Montana.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.